Vilya Launches to Design a New Transformational Class of Medicines That Precisely Target Disease Biology
A team of scientists at Institute of Protein Design led by David Baker, Ph.D., and ARCH Venture Partners launch Vilya to create a new transformational class of medicines Paper published today in Cell describes the ground-breaking research behind Vilya’s foundational technology leveraging advanced computational approaches to design novel molecules, never before found in nature, with … [Read more…]
